Considering the structural features of a group of known potent inhibitors of human platelet aggregation containing hydrazone structural backbone, a series of novel hydrazone derivatives of 2-hydrazinyl-1,3,4-thiadi azole were synthesized using a one-pot process and tested for their inhibitory activity against platelet aggregation induced by arachidonic acid and ADP. Among the derivatives, compounds 3l, 3o and 3p exhibited the highest antiplatelet aggregation activity. The derivatives were also screened for their potential antimycobacterial activity and compounds 3g, 3k, 3p and 3q were among the most active compounds.
Platelet activation starts the initial steps in development of thromboembolic disorders including cardiovascular and cerebrovascular events; the major causes of death in the industrial countries and also worldwide. 1, 2) Based on the role of platelets in initiation and progression of these diseases, some medications have been developed that target the biochemical pathways triggering or mediating platelet activation, self-affinity and aggregation.
The medications of clinical importance include: acetylsalicylic acid (a nonselective irreversible inhibitor of the enzyme cyclooxygenase) which prevents the transformation of arachidonic acid (AA) to its potent proaggregatory metabolite thromboxane A 2 and clopidogrel (an irreversible antagonist of P2Y 12 ) which blocks the activation of platelet purinergic recepteors of P2Y family (mainly P2Y 12 ) by adenosine diphosphate (ADP), another potent agonist of platelet aggregation. 2, 3) However, some undesired effects are associated with the use of these agents. Bleeding is the major side effect of both drugs. 4) Undesired complications such as neutropenia and thrombotic thrombocytopenic purpura (TTP) pose limitation on the antiplatelet therapies using clopidogrel. 4, 5) Resistance to both drugs is another problem that further complicates the anti-platelet therapy. 6) Considering the above mentioned limitations of antiplatelet drugs, research aiming at introducing new therapeutic agents with unique modes of action, high efficacy and improved safety is strongly demanding.
Hydrazone derivatives are an interesting group of compounds with various reported biological properties. They also hold a place in the area of antiplatelet drug discovery and many interesting studies have been performed focused on the development of hydrazone derivatives as inhibitors of platelet aggregation. Coquelet et al. have reported some arylhydrazone derivatives of aryl methyl ketones as inhibitors of platelet cyclooxygenase (COX) and lipoxygenase (LOX), blocking the transformation of arachidonic acid to its proaggregatory metabolites. 7) In light of the finding of this study, Barreiro et al. in a series of studies managed to develop some new hydrazones which effectively inhibited platelet aggregation with selective inhibitory activity toward platelet aggregation induced by arachidonic acid. They found active group of hydrazones with arylsulfonate acylhydrazone, 8) phenothiazine-1-acylhydrazone, 9) N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone 10) and pyrazolylhydrazone 11) structures. Although numerous derivatives have been found to exhibit antiplatelet activity in these studies, they share a strongly preserved structural backbone that is two (hetero) aromatic ring systems linked by a hydrazone bond (Fig. 1 ).
Many derivatizations have been made in both Ar 1 and Ar 2 positions and introduction of both carbocyclic and heterocyclic aromatic rings in each position led to active derivatives. Considering this background, in the present study by an isosteric substitution strategy, some hydrazone analogues have been designed and prepared as potential antiplatelet derivatives by introducing a thiadiazole ring in Ar 1 position and various carbocyclic and heterocyclic aromatic rings in Ar 2 position (Fig. 2) . This paper reports the preparation and inhibitory activity of the above mentioned derivatives against platelet aggregation induced by AA and ADP.
Regular Article * To whom correspondence should be addressed. e-mail: kobarfard@sbmu.ac.ir By reviewing the studies focused on antimycobacterial drug discovery and based on our previous experiences in this area, we found that the structural features of the newly designed hydrazone derivatives, would give them the possibility to be considered as suitable candidates to be tested for their potential antimycobacterial activity. The evidence comes from the available background of hydrazone derivatives and specially (thio) semicarbazones in antitubercular drug discovery and drug therapy. Some thiosemicarbazone derivatives known to possess antitubercular activity are shown in Fig. 3 . The mechanism of action of these compounds has not been firmly determined, but studies on thiacetazone suggests that this compound undergoes metabolic activation in Mycobacterium tuberculosis, producing reactive intermediate(s) that interfere with the synthesis of mycolic acid and hence integrity of the cell wall. [12] [13] [14] In a general view, these derivatives are distinguished by a thiosemicarbazone moiety linked via an imine bond to an aromatic ring system. In this regard, the newly designed hydrazone derivatives could be considered as a cyclic version of thiosemicarbazones with the thioamide moiety incorporated in a thiadiazole ring (Fig. 4) .
A new chemical entity, regardless of the rationale behind its design and synthesis, could be considered as an unexplored subject in medicinal chemistry that unanticipated biological activities may be observed for it when tested against different biotargets. This is particularly beneficial in the early stages of hit identification for those groups of diseases whose statuses are on WHO alert, such as Tuberculosis. Following nearly three decades of negligence, there is now renewed interest in the development of new drugs for the treatment and prevention of tuberculosis.
Considering the structural features for the designed compounds in the present study, anti mycobacterial activity is also expected for them beside anti platelet activity.
Therefore, in addition to antiplatelet activity, the antimycobacterial activity of the new derivatives was also assessed against Mycobacterium bovis BCG and the results have been discussed in this paper.
An inherent issue associated to this type of approach is the fact that these compounds can show promiscuous activity for both platelet and mycobacterium. Therefore, selectivity considerations have to be addressed very early after the preliminary activities are assessed.
Chemistry The synthetic procedure is illustrated in Chart 1. To prepare the desired derivatives, a one-pot procedure was employed: the selected aldehydes were added to thiocarbohydrazide (I) in glacial acetic acid as the solvent and within a time interval triethyl orthoformate was added and the final desired compounds were obtained upon heating the mixture for three hours.
In this synthetic procedure as shown in Chart 1, two main steps are distinguishable: the first step is the formation of monothiocarbohydrazone intermediates (2) resulted by reacting thiocarbohydrazide with equimolar amounts of desired aldehydes; and the second step is the cyclization of monothiocarbohydrazones in the presence of triethyl orthoformate leading to the compounds 3a-r.
To ascertain the validity of the proposed intermediate 2, in the case of compounds 3q and 3r, the primary reaction mixture was added to water before the addition of triethyl orthoformate and the solid mass thus obtained was analyzed by spectroscopic methods such as IR and 1 H-NMR. In the NMR spectra of these derivatives, the presence of D 2 O exchangeable peaks related to thiocarbohydrazone N-H protons and indole N-H and also the peaks assigned to imine and indole C-H protons confirms the formation of monothiocarbohydrazones of series 2 which were not isolated in the synthetic procedure of the other final derivatives (Fig. 6) . Synthesis of the mentioned monothiocarbohydrazones was also tried in ethanol/ water solution and few drops of glacial acetic acid and similar results were obtained, but preparation of the derivatives by the described one-pot procedure proved to be more convenient and accompanied by higher yields ranging from 49 to 85%. The structures of the final hydrazone derivatives 3a-r were confirmed by different spectroscopic methods. IR, NMR and MASS data and CHNS elemental analysis are in agreement with the proposed structures. In the IR spectra the N-H stretch bond appeared as weak, vanishing and broad band in the range of 3350-3500 cm −1 or was not observed at all. In the region between 1605-1620 cm −1 the medium intensity bands were observed which could be assigned to the stretching of C= N bonds present in the synthesized derivatives. In the 1 H-NMR spectra, the singlet at 12.03-12.80 ppm was assigned to N-H proton, which was confirmed by D 2 O exchange experiments. Two singlet peaks were distinguishable in the spectra, one resonating at 8.76-8.87 ppm and the other at 7.96-8.45. These two were assigned to thiadiazole H and imine H respectively. The assignment of the remaining peaks of the spectra appearing in the aromatic zone was straightforward because of their splitting patterns and coupling constants. In the 13 C-NMR spectra the peaks at ca. 170 ppm and ca. 144 ppm are characteristic for C-2 and C-5 of thiadiazole ring, since these two peaks are observed in 2-amino-1,3,4-thiadiazole spectra (171 ppm for C-2 and 144 ppm for C-5).
17)
Biological Activity Evaluation The in vitro antiplatelet aggregation activity was evaluated using turbidimetric method reported by Born and Cross 18) on an APACT 4004 aggregometer.
The tests were performed using human platelet-rich plasma (PRP) and aggregation was induced by AA or ADP. Indomethacin and aspirin were used as standard drugs in this test. The antimycobacterial activity of the compounds was evaluated by the broth microtiter dilution method 19) against My cobacterium bovis BCG (1173P2) and ethambutol and thiacetazone were used as standard drugs. The minimal inhibition concentration (MIC) was defined as the lowest concentration which could inhibit the bacterial growth.
Results and Discussion
The antiplatelet aggregation activity of the derivatives is listed in Table 1 . All the tested derivatives effectively inhibited platelet aggregation higher than 50% at 100 µm concentration. The majority of the compounds showed lower IC 50 values than that of aspirin and among them, compounds 3l, 3o and 3p exhibited comparable IC 50 values to that of indomethacin, a potent inhibitor of the enzyme COX. The results show that the tested compounds have a similar activity profile to those of previously studied hydrazone derivatives, that is they inhibited AA-induced platelet aggregation more effectively than once ADP was used as inducer. However, compound 3n showed satisfying activity with IC 50 value of 18.1 µm against ADP-induced platelet aggregation; notably that this derivatives proved to be effective to inhibit platelet aggregation induced by both ADP and AA.
Of the most potent derivatives, compounds 3o and 3p with IC 50 values of 2.2 µm and 3.8 µm both contain five membered electron-rich heterocyclic rings and this would suggest that the existence of these ring systems can be an important factor affecting the antiplatelet activity. This has been confirmed by the previous studies, as Coquelet et al. in their study found 2-acetylthiophene-2-thiazolylhydrazone as the most potent derivative exerting dual inhibition of COX/LOX. 7) Comparing the structures of this compound and compound 3p shows that these two have a high extent of similarity; suggesting that they also may share common mechanisms of action and structure-activity relationships (SARs) (Fig. 7) . This is also in line with the findings of Barreiro's group to discover some derivatives with furan substituent as potent inhibitors of AAinduced platelet aggregation. 11) Of the synthesized derivatives, compound 3n with dual inhibition of ADP/AA-induced platelet aggregation and compounds 3l, 3o and 3p as the most active inhibitors of AAinduced platelet aggregation have molecular weights ranging from 194 to 249 and C logP values ranging from 2.23 to 3.18. Therefore the mentioned derivatives have ideal physicochemical characteristics to be considered as starting points for further lead optimization studies in the area of antiplatelet aggregation drug research.
The anti-mycobacterial activitis and C logP values of the derivatives are listed in Table 2 . The most potent derivatives against Mycobacterium bovis BCG include 3g with 4-chlorophenyl, 3k with 2-nitrophenyl, 3p with 2-thienyl and 3q with 3-indolyl substituents, all with MIC value of 7.8 µg/mL. The derivatives containing 3-fluorophenyl 3c (MIC= 15.62 µg/mL), phenyl 3a (31.25 µg/mL) and 3-pyridyl 3n (46.87 µg/mL) fall into the lower levels with moderate activity. Among the most potent derivatives, compounds 3p and 3q contain electron rich heterocyclic rings in their structures while compounds 3g and 3k contain carbocyclic rings with electron-withdrawing substituents. Investigating the possible relationship between C logP and MIC values suggests an optimal C logP for the antitubercular activity of the studied derivatives, since the C logP values calculated for the most potent derivatives range between approximately 3 to 4. This is in agreement with the observation that bromophenyl containing derivatives 3h-j (C logP=4.0) and 5-bromoindolyl substituted 3r (C logP=4.17) with higher lipophilic characters and compounds of the other extremity including 3n (C logP=2.23) and 3o (C logP=2.41) fail to exert a satisfactory anti-tubercular activity. Analysis of the other physicochemical parameters including surface area, molecular volume, refractivity and polarizability did not lead to extracting a firm correlation between MICs and the mentioned parameters. This could be because of the complexity of the action mechanism of the studied derivatives or the complexity of the relationship between physicochemical parameters and the observed activities, so that several parameters with different orders of strength may affect the biological activity of the derivatives.
The synthesized derivatives showed promising antiplatelet aggregation activity and also antimycobacterial activity. The results obtained in this study gave us valuable clues to conduct our further works in antiplatelet and antimycobacterial drug research, some of which are already in progress by our group.
Conclusion
This paper describes a class of novel aromatic aldehyde 2-thiadiazolyl hydrazones designed by considering the structural features of the previously reported hydrazone derivatives proved to be active inhibitors of platelet aggregation. The derivatives were prepared by a one-pot procedure and evaluated for their antiplatelet aggregation activity using AA and ADP as aggregation inducers. The derivatives effectively inhibited platelet aggregation at 100 µm concentration and some of them exhibited inhibitory activities comparable to those of aspirin and indomethacin. Synthesis and study of anti platelet activity of 5-substituted thiadiazole derivatives will provide valuable information about the SAR of this group of compounds.
The derivatives were also tested for their antimycobacterial activity and some showed activity with satisfying MICs.
Experimental
General All the solvents and reagents were freshly used. The reactions were monitored using TLC silica gel 60 F254 plates (Merck) with chloroform-methanol (20 : 1) as mobile phase. Melting points were obtained by an Electrothermal 9100 apparatus and are uncorrected. The Infrared spectra were recorded by a Perkin-Elmer 843 spectrometer with KBr as diluent. Proton nuclear magnetic resonance ( The C logP values were calculated from the server tool available online at (www.organic-chemistry.org). Other physicochemical parameters including surface area, molecular volume, refractivity and polarizability were calculated by Hyperchem 8.0 software. Thiocarbohydrazide (1) was prepared by heating a mixture of carbon disulfide and aqueous solution of hydrazine hydrate according to the known method.
20)
General Procedure for the Synthesis of Hydrazones (3a-r) A mixture of thiocarbohydrazide (0.21 g, 0.002 mol), the appropriate aldehydes (0.002 mol) and glacial acetic acid (1 mL) was heated for 20 min, then triethyl orthoformate (5 mL) was added and the mixture was heated under reflux for 3 h. The mixture was then cooled in an ice bath and the precipitates were filtered by vacuum. The solid thus obtained was recrystallized from an appropriate solvent to afford the title compounds. In Vitro Evaluation of Antiplatelet Aggregation Activity The blood samples were obtained from healthy volunteers with negative history of smoking or taking any medications since 14 d prior to blood collection. To blood samples was added trisodium citrate dihydrate 3.8% (1 part citrate, 9 part blood) and centrifuged at 1000 rpm for 8 min to obtain PRP. The remaining was centrifuged at 3000 rpm for 15 min and PPP was collected from the above layer which was used as the test blank. The platelet count was adjusted to 250000 plts/mL by diluting PRP with appropriate amount of PPP once needed. Of the test compounds previously dissolved in dimethyl sulfoxide (DMSO), 1 µL was added to 200 µL of PRP and incubated at 37°C for 5 min. To induce platelet aggregation, a solution of ADP (5 µm) or arachidonic acid (1.25 mg/mL) was added to the samples and aggregation was measured using APACT 4004 aggregometer for a 5-minute period. DMSO (0.5% v/v) was used as negative control and indomethacin and aspirin as standard drugs. Platelet aggregation inhibition (%) was calculated by the following formula:
inhibition % [1 ( / )] 100  = × D S Where: D, platelet aggregation in the presence of test compounds; S, platelet aggregation in the presence of DMSO.
Compounds were tested at the initial concentration of 100 µm and IC 50 was calculated from log(concentration)−inhibition (%) diagram for those that inhibited the platelet aggregation by 50% or more. IC 50 in this test was defined as the concentration at which the test compound inhibits platelet aggregation by 50%.
In Vitro Evaluation of Antimycobacterial Activity The test compounds were initially dissolved in DMSO to give a concentration of 1 or 2 mg/L. To all wells of the micro-plates was added 100 µL of freshly prepared Middle broke 7H9 medium (Himedia, India), except the first column. Then distilled water (200 µL) was added to the first column of 96 well plates to minimize the medium evaporation in the wells during incubation. Of the DMSO solution of the test compounds with the primary concentration of 1 or 2 mg/L, 1000 µL was added to the wells of the first row and addition of the compounds to the other rows was made by serial dilution with each concentration assayed in duplicate. Then 100 µL of the microbial suspension of BCG (1173P2) which had been prepared with standard concentration of 0.5 Mcfarland and diluted with 1 : 10 proportion by the distilled water, was added to all the test wells. Plates were then sealed and incubated for 4 d at 37°C. After 4 d, 12 µL of 10% Tween 80 and 20 µL of 0.01% Alamar blue (Himedia, India) were added to the test wells. The results were assessed after 24 and 48 h. The blue color was interpreted as no bacterial growth and wells with a well-defined pink color were scored as positive for growth. The MIC (minimal inhibition concentration) was defined as the lowest drug concentration that prevented a color change from blue to pink. Ethambutol (Irandaru, Tehran) and thiacetazone were used as standard drugs and DMSO as negative control.
